Table 2 Clinical characteristics and SARS-CoV-2 infection outcomes of CGL subjects with reactive (SARS-CoV-2+) and non-reactive (SARS-CoV-2) serologic tests

Patients, n

8 (36.3%)

14 (63.6%)

Female, n (%)

5 (62.5%)

8 (57.1%)

> 0.999

Age (years), median (min-max)

13.5 (1–37)

22.5 (7–42)

0.355

Under 18 years, n (%)

5 (62.5%)

5 (35.7%)

0.378

Mutation

 AGPAT2, n (%)

6 (75%)

10 (71.4%)

> 0.999

 BSCL2, n (%)

2 (25%)

4 (28.6%)

> 0.999

Metabolic profile

 A1C median (min–max)

7.6 (5–11.2)

7.05 (5–11.4)

0.86

 TC median (min–max)

149 (78–213)

158.5 (112–235)

0.159

 HDL median (min–max)

30 (22–41)

29 (20–47)

0.909

 Non-HDL median (min–max)

109.5 (56–172)

125.5 (83–200)

0.111

 TG median (min–max)

141.5 (49–427)

410 (80–891)

0.023

Metabolic control

 A1C > 7.0%, n (%)**

4 (66%)

7 (58%)

> 0.999

 No-HDL > 100, n (%)

5 (62.5%)

12 (85.7%)

0.5492

 Hypertrygliceridemia*, n (%)

4 (50%)

10 (71.4%)

0.3864

Comorbidities

 DM, n (%)

6 (75%)

12 (85.7%)

0.602

 Duration of DM (years), median (min–max)

6.5 (0.1-19)

11 (0.1-21)

0.501

 Low HDL, n (%)

8 (100%)

14 (100%)

–

 Hypertriglyceridemia, n (%)

8 (100%)

13 (92.8%)

> 0.999

 Arterial hypertension, n (%)

1 (12.5%)

1 (7%)

> 0.999

Medicines in use

 Insulin, n (%)

4 (50%)

8 (57.2%)

> 0.999

 Daily dose of insulin median, IU/kg/day

2.1 (1.3–5.8)

1.5 (0.4-7.2)

0.57

 Metformin, n (%)

5 (62.5%)

13 (92.8%)

0.076

 Fibrate, n (%)

0

2 (14.3%)

0.5152

 Statine, n (%)

2 (25%)

5 (35.7%)

> 0.999

Clinical symptoms***

 Fever, n (%)

3 (37.5%)

3 (21.4%)

0.6244

 Cough, n (%)

1 (12.5%)

2 (14.2%)

> 0.999

 Sore throat, n (%)

1 (12.5%)

5 (35.7)

0.3512

 Myalgia, n (%)

0

3 (21.4%)

0.2727

 Fatigue, n (%)

0

0

–

 Dyspnea, n (%)

1 (12.5%)

2 (14.2%)

> 0.999

 Chest pain, n (%)

2 (25%)

1 (7.1%)

0.5273

 Nausea, n (%)

3 (37.5%)

1 (7.1%)

0.1167

 Diarrhea, n (%)

3 (37.5%)

3 (21.4%)

0.6244

 No symptoms, n (%)

5 (62.5%)

6 (42.8%)

0.6594

Outcomes

 Hospitalization, n (%)

0

 Death, n (%) 0

0